← Amphastar Pharmaceuticals, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $255.2m |
$240.2m
-5.87%
|
$294.7m
+22.69%
|
$322.4m
+9.40%
|
$349.8m
+8.53%
|
$437.8m
+25.13%
|
$499.0m
+13.98%
|
$644.4m
+29.14%
|
$732.0m
+13.59%
|
$719.9m
-1.65%
|
$730.0m
+1.41%
|
|
| Cost of Goods and Services Sold | $151.0m |
$149.4m
-1.06%
|
$187.7m
+25.64%
|
$190.4m
+1.47%
|
$206.5m
+8.44%
|
$238.0m
+15.26%
|
$250.1m
+5.08%
|
$293.3m
+17.25%
|
$358.1m
+22.11%
|
$363.8m
+1.60%
|
$381.9m
+4.97%
|
|
| Gross Profit | $104.2m |
$90.8m
-12.86%
|
$107.0m
+17.83%
|
$131.9m
+23.31%
|
$143.3m
+8.65%
|
$199.7m
+39.35%
|
$248.9m
+24.59%
|
$351.1m
+41.09%
|
$373.9m
+6.47%
|
$356.1m
-4.76%
|
$348.1m
-2.23%
|
|
| Research and Development Expense | $41.2m | $43.4m | $57.6m | $68.9m | $67.2m | $60.9m | $74.8m | $73.7m | $73.9m | $85.8m | $94.6m | |
| Selling and Marketing Expense | $5.5m | $6.5m | $8.2m | $12.8m | $14.8m | $17.5m | $21.5m | $28.9m | $37.8m | $43.9m | $139.3m | |
| General and Administrative Expense | $41.8m | $44.5m | $49.9m | $50.3m | $50.4m | $51.4m | $45.1m | $51.5m | $56.7m | $85.9m | $92.2m | |
| Amortization of Intangible Assets | $2.5m | $2.9m | $2.0m | $1.0m | $1.0m | $1.3m | $1.4m | $12.8m | $24.7m | $25.0m | — | |
| Operating Expenses | $88.5m | $91.7m | $115.6m | $132.0m | $132.4m | $129.9m | $141.4m | $154.1m | $168.4m | $215.7m | $233.8m | |
| Operating Income (Loss) | $15.7m |
($895k)
-105.70%
|
($8.6m)
-863.46%
|
($39k)
+99.55%
|
$11.0m
+28187.18%
|
$69.9m
+538.00%
|
$107.5m
+53.82%
|
$197.0m
+83.25%
|
$205.4m
+4.28%
|
$140.4m
-31.65%
|
$114.3m
-18.60%
|
|
| Other Nonoperating Income (Expense) | $8k | $2.9m | ($1.5m) | $59.4m | ($6.6m) | $14.5m | $9.1m | ($3.9m) | $4.1m | $23k | — | |
| Interest Expense (non-operating) | $1.0m | $826k | $243k | $119k | $374k | $885k | $1.8m | $27.2m | $30.3m | $25.5m | $26.1m | |
| Income (Loss) from Equity Method Investments | — | — | — | — | — | ($208k) | ($1.2m) | ($2.0m) | ($573k) | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $20.9m | $7.3m | $3.6m | $77.1m | $15.6m | $86.2m | $127.2m | $181.9m | $195.2m | $129.0m | $102.0m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $14.9m | $1.6m | ($9.9m) | $60.2m | $4.6m | $84.1m | $116.0m | $171.4m | $189.8m | $123.6m | $102.0m | |
| Current Income Tax Expense (Benefit) | $8.4m | ($5.6m) | $1.1m | $6.2m | $2.6m | $16.9m | $39.4m | $45.7m | $46.8m | ($3.1m) | $23.5m | |
| Income Tax Expense (Benefit) | $4.4m | ($2.9m) | ($3.3m) | $13.7m | $3.5m | $20.6m | $23.5m | $31.8m | $29.7m | $25.5m | $23.5m | |
| Net Income (Loss) Attributable to Parent | $10.5m |
$4.5m
-57.20%
|
($5.7m)
-227.28%
|
$48.9m
+952.89%
|
$1.4m
-97.13%
|
$62.1m
+4327.37%
|
$91.4m
+47.12%
|
$137.5m
+50.51%
|
$159.5m
+15.98%
|
$98.1m
-38.51%
|
$78.5m
-19.93%
|
|
| Net Income (Loss) Attributable to Noncontrolling Interest | — | — | ($922k) | ($2.4m) | ($306k) | $1.2m | — | — | — | — | $78.5m | |
| Earnings Per Share, Basic | $0.23 | $0.10 | ($0.12) | $1.04 | $0.03 | $1.30 | $1.88 | $2.85 | $3.29 | $2.10 | $1.74 | |
| Earnings Per Share, Diluted | $0.22 | $0.09 | ($0.12) | $0.98 | $0.03 | $1.25 | $1.74 | $2.60 | $3.06 | $2.03 | $1.69 | |
| Weighted Average Number of Shares Outstanding, Basic | 45.4m | 46.1m | 46.4m | 47.0m | 47.0m | 47.8m | 48.6m | 48.3m | 48.4m | 46.7m | 45.3m | |
| Weighted Average Number of Shares Outstanding, Diluted | 47.5m | 48.4m | 46.4m | 49.9m | 49.1m | 49.8m | 52.4m | 53.0m | 52.1m | 48.2m | 46.4m | |
| Additional Financial Items | ||||||||||||
| Capitalized Computer Software, Amortization | — | — | — | — | — | — | — | — | — | $0 | — |